Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Fuse Oncology, Inc.Fuse Oncology and Associated Medical Professionals of NY Launch Proof of Concept for End-to-End Radiation Oncology Workflow in UrologySyracuse practice, part of U.S. Urology Partners, a General Atlantic company, will run a first proof of concept of FuseRx, with ACRO clinical pathways built in, at its radiation oncology program in Syracuse SYRACUSE, N.Y. and BOONE, N.C., Sept. 28, 2026 -- Fuse Oncology and...
- ROSEN, A LEADING NATIONAL FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
- NetflixScrubs On: ‘Miracles of the ER’ Premieres November 12 on NetflixCompanies: Netflix, Inc.Starring Wallace Huo, Cheryl Yang, Kent Tsai, Chan Tzu-hsuan, Payne Peng and more, the medical workplace drama delivers high stakes and plenty of heart.
- Ascletis Pharma Inc.Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential...
- Yili stellt auf der globalen FAO-Konferenz Chinas Modell der Symbiose in der gesamten Wertschöpfungskette der Milchwirtschaft vorROM, 29. September 2026 -- Die Yili Group stellte auf der ersten globalen Konferenz der Ernährungs- und Landwirtschaftsorganisation der Vereinten Nationen (FAO) zum Thema „One Health in Agrifood Systems" ein in China ansässiges Modell für die Symbiose entlang der gesamten...
- Belite Bio, IncBelite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesBelite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Euretina Innovation Spotlight (EIS) being held on September 30, 2026, and Euretina being held on October 1-4, 2026, in Vienna, Austria.
- Yili présente son modèle chinois de symbiose laitière sur l'ensemble de la chaîne de valeur à la Conférence mondiale de la FAOROME, 29 septembre 2026 -- Yili Group a présenté son modèle chinois de symbiose couvrant l'ensemble de la chaîne de valeur lors de la première Conférence mondiale sur les actions en faveur de l'approche One Health dans les systèmes agroalimentaires, organisée par...
- Blue Shield of CaliforniaBLUE SHIELD OF CALIFORNIA LAUNCHES FOOD AS HEALTH INITIATIVE WITH SUPPORT FOR ALAMEDA COUNTY COMMUNITY FOOD BANKNonprofit health plan commits $600,000 for a statewide initiative; Alameda County Community Food Bank is first collaboration with $300,000 support to improve health and well-being — Blue Shield of California today announced a new statewide...
- Truth InitiativeFDA Must Maintain Strong Scientific Review Process for New Tobacco Products and Crack Down on Illegal Marketplace to Protect Public HealthStatement from Kathy Crosby, CEO and President of Truth Initiative — Today, the U.S. Food and Drug Administration announced that it plans to evaluate changes to the framework for applications for new tobacco products like e-cigarettes and nicotine...
- MDCloneUniversity Medical Center Göttingen Takes a New Approach to the Use of Clinical DataUMG is advancing its data integration center and becomes the first German university hospital to introduce MDClone's internationally established ADAMS model. Göttingen, Germany and — The University Medical Center Göttingen (UMG) is the...
- Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE® (tiratricol) for Patients with MCT8 DeficiencySTOCKHOLM, SWEDEN, Sept. 28 2026. – Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved EMCITATE® (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome). EMCITATE is not recommended for the treatment of primary hypothyroidism. EMCITATE is the first FDA-approved treatment option for patients with MCT8 deficiency in the United States.
- Anonymous Health Achieves HITRUST e1 Certification for Its Behavioral Health AI PlatformSAN FRANCISCO, September 28, 2026--Anonymous Health, a healthcare technology company purpose-built for behavioral health, ABA therapy, and other healthcare providers, today announced that the Anonymous Health Platform has achieved HITRUST Essentials, 1-year (e1) Certification for cybersecurity and information protection.